{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:42:54Z","timestamp":1773114174702,"version":"3.50.1"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0012_s_014_w2aab3b7c26b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peritoneal metastases from gynecologic and gastrointestinal cancer is of increasing interest to surgical and medical oncologists because of newly recognized benefits of treatment. In contrast to prior outcomes, prolonged disease-free survival and cure have been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0012_s_015_w2aab3b7c26b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To date, the benefits are to use complete surgical removal of the peritoneal metastases combined with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered in the operating room. To supplement the local-regional control, normothermic intraperitoneal chemotherapy used long term (NIPEC-LT) and delivered by an intraperitoneal port has been explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0012_s_016_w2aab3b7c26b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In three high grade malignancies with the preponderance of cytoreductive surgery (CRS) and HIPEC treatment failures within the peritoneal space, NIPEC-LT has been favorably reported in the oncology literature. In ovarian cancer and malignant peritoneal mesothelioma the NIPEC-LT is used an adjuvant treatment in an attempt to preserve a surgical complete response of CRS. In gastric cancer, NIPEC-LT is given as a neoadjuvant treatment with responders going on to radical surgical resection. Responses are monitored by laparoscopy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0012_s_017_w2aab3b7c26b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This overview highlights benefits of NIPEC-LT in three diseases where benefits from CRS and HIPEC have been recognized but that local-regional failures persist. Improved results with NIPEC-LT have been reviewed for ovarian cancer, gastric cancer, and peritoneal mesothelioma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0012","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T09:20:19Z","timestamp":1496395219000},"page":"85-93","source":"Crossref","is-referenced-by-count":14,"title":["Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview"],"prefix":"10.1515","volume":"2","author":[{"given":"Paul H.","family":"Sugarbaker","sequence":"first","affiliation":[{"name":"Center for Gastrointestinal Malignancies , MedStar Washington Hospital Center , 106 Irving St., NW, Suite 3900 , Washington 20010, DC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"2025120909204646695_j_pp-2017-0012_ref_001_w2aab3b7c26b1b6b1ab2b1b1Aa","unstructured":"Halkia E, Sugarbaker PH. Neoadjuvant, adjuvant and long-term IP\/IV chemotherapy, HIPEC, EPIC for ovarian cancer. J Peritoneum in press."},{"key":"2025120909204646695_j_pp-2017-0012_ref_002_w2aab3b7c26b1b6b1ab2b1b2Aa","unstructured":"Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy. Curr Res in Cancer 2009;3:179\u2013203."},{"key":"2025120909204646695_j_pp-2017-0012_ref_003_w2aab3b7c26b1b6b1ab2b1b3Aa","unstructured":"Sugarbaker PH, van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol 2016;7:29\u201344."},{"key":"2025120909204646695_j_pp-2017-0012_ref_004_w2aab3b7c26b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Improving oncologic outcomes for colorectal cancer at high risk for local-regional recurrence with novel surgical techniques. Expert Rev Gastroenterol Hepatol 2016;10:205\u201313.","DOI":"10.1586\/17474124.2016.1110019"},{"key":"2025120909204646695_j_pp-2017-0012_ref_005_w2aab3b7c26b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Optimization of patient selection for surgical approach to peritoneal metastases from gastrointestinal cancer using cytoreductive surgery and perioperative cancer. Curr Colorectal Cancer Rep 2014;10:272\u20138.","DOI":"10.1007\/s11888-014-0226-5"},{"key":"2025120909204646695_j_pp-2017-0012_ref_006_w2aab3b7c26b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2015;33:1460\u20136.","DOI":"10.1200\/JCO.2014.55.9898"},{"key":"2025120909204646695_j_pp-2017-0012_ref_007_w2aab3b7c26b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950\u20135.","DOI":"10.1056\/NEJM199612263352603"},{"key":"2025120909204646695_j_pp-2017-0012_ref_008_w2aab3b7c26b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 2001;19:1001\u20137.","DOI":"10.1200\/JCO.2001.19.4.1001"},{"key":"2025120909204646695_j_pp-2017-0012_ref_009_w2aab3b7c26b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015 May;22:1570\u20135.","DOI":"10.1245\/s10434-014-4157-9"},{"key":"2025120909204646695_j_pp-2017-0012_ref_010_w2aab3b7c26b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1\u201311.","DOI":"10.1016\/0360-3016(82)90377-7"},{"key":"2025120909204646695_j_pp-2017-0012_ref_011_w2aab3b7c26b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Wisbeck WM, Becher EM, Russell AH. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol J Eur Soc Ther Radiol Oncol 1986;7:13\u20138.","DOI":"10.1016\/S0167-8140(86)80120-7"},{"key":"2025120909204646695_j_pp-2017-0012_ref_012_w2aab3b7c26b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990;19:1357\u201362.","DOI":"10.1016\/0360-3016(90)90344-J"},{"key":"2025120909204646695_j_pp-2017-0012_ref_013_w2aab3b7c26b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Wils J, Meyer HJ, Wilke H. Current status and future directions in the treatment of localized gastric cancer. Ann Oncol 1994;5:69\u201372.","DOI":"10.1093\/annonc\/5.suppl_3.S69"},{"key":"2025120909204646695_j_pp-2017-0012_ref_014_w2aab3b7c26b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418\u201325.","DOI":"10.1007\/BF01655804"},{"key":"2025120909204646695_j_pp-2017-0012_ref_015_w2aab3b7c26b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Kaibara N, Sumi K, Yonekawa M, Ohta M, Makino M, Kimura O, et al. Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer? Am J Surg 1990;159:218\u201321.","DOI":"10.1016\/S0002-9610(05)80265-X"},{"key":"2025120909204646695_j_pp-2017-0012_ref_016_w2aab3b7c26b1b6b1ab2b1c16Aa","unstructured":"Korenaga D, Moriguchi S, Orita H, Kakeji Y, Haraguchi M, Maehara Y, et al. Trends in survival rates in Japanese patients with advanced carcinoma of the stomach. Surg Gynecol Obstet 1992;174:387\u201393."},{"key":"2025120909204646695_j_pp-2017-0012_ref_017_w2aab3b7c26b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Boku T, Nakane Y, Minoura T, Takada H, Yamamura M, Hioki K, et al. Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg 1990;77:436\u20139.","DOI":"10.1002\/bjs.1800770425"},{"key":"2025120909204646695_j_pp-2017-0012_ref_018_w2aab3b7c26b1b6b1ab2b1c18Aa","unstructured":"Sethna KS, Sugarbaker PH. New prospects for the control of peritoneal surface dissemination of gastric cancer using perioperative intraperitoneal chemotherapy. Cancer Ther 2004;2:79\u201384."},{"key":"2025120909204646695_j_pp-2017-0012_ref_019_w2aab3b7c26b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Arvieux C. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370\u20137.","DOI":"10.1245\/s10434-010-1039-7"},{"key":"2025120909204646695_j_pp-2017-0012_ref_020_w2aab3b7c26b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 2016;42:1123\u201331.","DOI":"10.1016\/j.ejso.2016.03.016"},{"key":"2025120909204646695_j_pp-2017-0012_ref_021_w2aab3b7c26b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, et al. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol 2014;21:1448\u201355.","DOI":"10.1245\/s10434-013-3327-5"},{"key":"2025120909204646695_j_pp-2017-0012_ref_022_w2aab3b7c26b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997;79:884\u201391.","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C"},{"key":"2025120909204646695_j_pp-2017-0012_ref_023_w2aab3b7c26b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Yang X-J, Huang C-Q, Suo T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18:1575\u201381.","DOI":"10.1245\/s10434-011-1631-5"},{"key":"2025120909204646695_j_pp-2017-0012_ref_024_w2aab3b7c26b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010;2:85\u201397.","DOI":"10.4251\/wjgo.v2.i2.85"},{"key":"2025120909204646695_j_pp-2017-0012_ref_025_w2aab3b7c26b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003;21:233\u201348.","DOI":"10.1002\/ssu.10042"},{"key":"2025120909204646695_j_pp-2017-0012_ref_026_w2aab3b7c26b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Canbay E, Mizumoto A, Ichinose M. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol 2014;21:1147\u201352.","DOI":"10.1245\/s10434-013-3443-2"},{"key":"2025120909204646695_j_pp-2017-0012_ref_027_w2aab3b7c26b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Kitayama J, Ishigami H, Yamaguchi H. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol 2014;21:539\u201346.","DOI":"10.1245\/s10434-013-3208-y"},{"key":"2025120909204646695_j_pp-2017-0012_ref_028_w2aab3b7c26b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29\u201342.","DOI":"10.1097\/00000658-199501000-00004"},{"key":"2025120909204646695_j_pp-2017-0012_ref_029_w2aab3b7c26b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 2012;105:38\u201342.","DOI":"10.1002\/jso.22057"},{"key":"2025120909204646695_j_pp-2017-0012_ref_030_w2aab3b7c26b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Oncol 2007;18:827\u201334.","DOI":"10.1093\/annonc\/mdl428"},{"key":"2025120909204646695_j_pp-2017-0012_ref_031_w2aab3b7c26b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686\u201393.","DOI":"10.1245\/s10434-014-3978-x"},{"key":"2025120909204646695_j_pp-2017-0012_ref_032_w2aab3b7c26b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006;17:1615\u201319.","DOI":"10.1093\/annonc\/mdl060"},{"key":"2025120909204646695_j_pp-2017-0012_ref_033_w2aab3b7c26b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008;98:268\u201372.","DOI":"10.1002\/jso.21055"},{"key":"2025120909204646695_j_pp-2017-0012_ref_034_w2aab3b7c26b1b6b1ab2b1c34Aa","unstructured":"International PSOGI Registry on Peritoneal Mesothelioma. Available at: http:\/\/test.dinamoweb.net\/p_mesotelioma\/"},{"key":"2025120909204646695_j_pp-2017-0012_ref_035_w2aab3b7c26b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol 2009;100:321\u20138.","DOI":"10.1002\/jso.21388"},{"key":"2025120909204646695_j_pp-2017-0012_ref_036_w2aab3b7c26b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Chang D. Long-term intraperitoneal chemotherapy for patients with malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 2017 Jan 29. pii: S0748-7983(17)30059-8. doi:10.1016\/j.ejso.2017.01.009. [Epub ahead of print]","DOI":"10.1016\/j.ejso.2017.01.009"},{"key":"2025120909204646695_j_pp-2017-0012_ref_037_w2aab3b7c26b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma \u2013 a prospective study of 70 consecutive cases. Ann Surg Oncol 2007;14:515\u201325.","DOI":"10.1245\/s10434-006-9187-5"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/2\/article-p85.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0012\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:41:27Z","timestamp":1765276887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0012\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,6]]},"published-print":{"date-parts":[[2017,6,5]]}},"alternative-id":["10.1515\/pp-2017-0012"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0012","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}